Stock analysis, price data, and AI-powered insights for Cencora (COR).
Cencora operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for COR.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). COR Stock Intelligence Report. [stoxpulse.com/stocks/cor]
Disclaimer: The information on this page about Cencora (COR) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Cencora.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 2%
Jun 30
NALLY bought 113 shares
Jul 31
Cooper bought 97 shares
Jul 31
AbbVie vs. Abbott Laboratories: Which Healthcare S...
3d ago
Will Pharma and Specialty Demand Boost Cardinal He...
3d ago
StoxPulse AI results for COR: Pulse Score 56/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$62.02B
P/E Ratio
39.9
EPS
$3.94
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sep 25
+0.4%
Dec 25
+0.0%
Mar 26
-2.3%
Jun 26
+2.0%
Beat estimates 3 of 4 quarters (75%)
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?
Dividend Champion, Contender, And Challenger Highlights: Week Of August 9
Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $346
JP Morgan Maintains Overweight on Cencora, Raises Price Target to $390
Terrible Jobs Report Sparks Rally In AI and Tech: 10 Stocks Leading Friday's Surge
UBS Maintains Buy on Cencora, Raises Price Target to $430
Camino Announces $5.0 Million Brokered Private Placement of Units and Concurrent $9.5 Million Non-Brokered Private Placement of Convertible Debentures